Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study.

Coker LH, Hogan PE, Bryan NR, Kuller LH, Margolis KL, Bettermann K, Wallace RB, Lao Z, Freeman R, Stefanick ML, Shumaker SA.

Neurology. 2009 Jan 13;72(2):125-34. doi: 10.1212/01.wnl.0000339036.88842.9e.

2.

Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study.

Resnick SM, Espeland MA, Jaramillo SA, Hirsch C, Stefanick ML, Murray AM, Ockene J, Davatzikos C.

Neurology. 2009 Jan 13;72(2):135-42. doi: 10.1212/01.wnl.0000339037.76336.cf.

3.

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH; Women's Health Initiative Memory Study..

JAMA. 2004 Jun 23;291(24):2947-58.

PMID:
15213206
4.

Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.

Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J; Women's Health Initiative Memory Study..

JAMA. 2004 Jun 23;291(24):2959-68.

PMID:
15213207
5.

Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS).

Coker LH, Espeland MA, Rapp SR, Legault C, Resnick SM, Hogan P, Gaussoin S, Dailey M, Shumaker SA.

J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):304-10. doi: 10.1016/j.jsbmb.2009.11.007.

6.

Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies.

Coker LH, Espeland MA, Hogan PE, Resnick SM, Bryan RN, Robinson JG, Goveas JS, Davatzikos C, Kuller LH, Williamson JD, Bushnell CD, Shumaker SA; WHIMS-MRI Study Group..

Neurology. 2014 Feb 4;82(5):427-34. doi: 10.1212/WNL.0000000000000079.

7.

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D; WHIMS Investigators..

JAMA. 2003 May 28;289(20):2663-72.

PMID:
12771113
8.

Brain volumes, cognitive impairment, and conjugated equine estrogens.

Espeland MA, Tindle HA, Bushnell CA, Jaramillo SA, Kuller LH, Margolis KL, Mysiw WJ, Maldjian JA, Melhem ER, Resnick SM; Women's Health Initiative Memory Study..

J Gerontol A Biol Sci Med Sci. 2009 Dec;64(12):1243-50. doi: 10.1093/gerona/glp128.

9.

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; WHIMS Investigators..

JAMA. 2003 May 28;289(20):2651-62.

PMID:
12771112
10.

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB.

JAMA. 2013 Oct 2;310(13):1353-68. doi: 10.1001/jama.2013.278040.

11.

Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on.

Maki PM, Henderson VW.

Climacteric. 2012 Jun;15(3):256-62. doi: 10.3109/13697137.2012.660613. Review.

12.

The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y).

Vaughan L, Espeland MA, Snively B, Shumaker SA, Rapp SR, Shupe J, Robinson JG, Sarto GE, Resnick SM; Women's Health Initiative Memory Study of Younger Women (WHIMS-Y) Study Group..

Brain Res. 2013 Jun 13;1514:3-11. doi: 10.1016/j.brainres.2013.03.047.

13.

[Hormone replacement therapy and cognitive function].

Huang CP, Hong CT, Huang IT.

Acta Neurol Taiwan. 2006 Dec;15(4):273-7. Chinese.

PMID:
17214093
14.

Effects of combination estrogen plus progestin hormone treatment on cognition and affect.

Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P, Ockene JK, Shumaker SA; Women's Health Initiative Study of Cognitive Aging Investigators..

J Clin Endocrinol Metab. 2006 May;91(5):1802-10.

PMID:
16522699
15.

Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects.

Zhao S, Chlebowski RT, Anderson GL, Kuller LH, Manson JE, Gass M, Patterson R, Rohan TE, Lane DS, Beresford SA, Lavasani S, Rossouw JE, Prentice RL.

Breast Cancer Res. 2014 Mar 26;16(2):R30. doi: 10.1186/bcr3632.

16.

Effects of estrogen with and without progestin on urinary incontinence.

Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, Aragaki A, Naughton MJ, Wallace RB, McNeeley SG.

JAMA. 2005 Feb 23;293(8):935-48.

PMID:
15728164
17.

Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years.

Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, Vaughan L, Robinson J, Rapp SR, Goveas JS, Wactawski-Wende J, Stefanick ML, Li W, Resnick SM; WHIMSY Study Group..

JAMA Intern Med. 2013 Aug 12;173(15):1429-36.

18.

Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.

Maalouf NM, Sato AH, Welch BJ, Howard BV, Cochrane BB, Sakhaee K, Robbins JA.

Arch Intern Med. 2010 Oct 11;170(18):1678-85. doi: 10.1001/archinternmed.2010.342.

19.

Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials.

Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson G, Chlebowski RT.

Breast Cancer Res Treat. 2012 Feb;132(1):275-85. doi: 10.1007/s10549-011-1848-9.

20.

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators..

JAMA. 2008 Mar 5;299(9):1036-45. doi: 10.1001/jama.299.9.1036.

PMID:
18319414

Supplemental Content

Support Center